NF-κB inhibition:: A double-edged sword in cancer?
NF-κB inhibition:: A double-edged sword in cancer?
复制标题
DOI：
10.1016/j.ejca.2006.01.011
复制
发表时间：
2006-04-01
影响因子：
8.4
通讯作者：
Ben-Neriah, Y
中科院分区：
文献类型：
--
作者：
Pikarsky, E;Ben-Neriah, Y
最近的几项小鼠癌症模型研究为nf - κ B在癌变中的关键作用提供了直接的遗传证据。虽然人们早就知道NF-kappa B是化疗耐药的关键介质，但现在清楚的是，转录因子在肿瘤发展中也起着重要作用，特别是在其早期阶段。然而，NF-kappa B在肿瘤发生中的作用比预期的要复杂得多，因为在一些模型中，NF-kappa B抑制会阻断肿瘤的发生，而在另一些模型中，它会促进肿瘤的发展。在本文中，我们回顾了目前的知识，并提出了一个一般的假设，试图解决这个明显的悖论。进一步的癌症模型研究应该有助于澄清这一问题，补充制药行业围绕NF-kappa B. (c) 2006 Elsevier Ltd的密集药物开发工作。版权所有。
Several recent studies of mouse models of cancer have provided direct genetic evidence for the critical role of NF-kappa B in carcinogenesis. While it has long been known that NF-kappa B is a key mediator of chemotherapy resistance, it is now clear that the transcription factor also has a major role in tumour development, particularly at its earlier phases. However, the role of NF-kappa B in tumourigenesis is more complex than anticipated, as in some models NF-kappa B inhibition blocks, whereas in others it facilitates, tumour development. In this paper we review current knowledge and suggest a general hypothesis that attempts to resolve this apparent paradox. Further cancer model studies should help to clarify this issue, complementing the intensive drug development effort of the pharmaceutical industry around NF-kappa B. (c) 2006 Elsevier Ltd. All rights reserved.